Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma

Non‐invasive monitoring of response to treatment of glioblastoma (GB) is nowadays carried out using MRI. MRS and MR spectroscopic imaging (MRSI) constitute promising tools for this undertaking. A temozolomide (TMZ) protocol was optimized for GL261 GB. Sixty‐three mice were studied by MRI/MRS/MRSI. T...

Full description

Saved in:
Bibliographic Details
Published in:NMR in biomedicine 2014-11, Vol.27 (11), p.1333-1345
Main Authors: Delgado-Goñi, Teresa, Julià-Sapé, Margarida, Candiota, Ana Paula, Pumarola, Martí, Arús, Carles
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents, Alkylating - administration & dosage
Antineoplastic Agents, Alkylating - analysis
Antineoplastic Agents, Alkylating - pharmacokinetics
Antineoplastic Agents, Alkylating - therapeutic use
Apoptosis
Brain - metabolism
Brain Neoplasms - chemistry
Brain Neoplasms - drug therapy
Brain Neoplasms - pathology
Cell Line, Tumor
Dacarbazine - administration & dosage
Dacarbazine - analogs & derivatives
Dacarbazine - analysis
Dacarbazine - pharmacokinetics
Dacarbazine - therapeutic use
DMSO
Drug Administration Schedule
Female
GL261 glioblastoma
Glioblastoma - chemistry
Glioblastoma - drug therapy
Glioblastoma - pathology
Magnetic Resonance Imaging - methods
Magnetic Resonance Spectroscopy - methods
Metabolome
Mice
Mice, Inbred C57BL
Mitosis
pattern recognition
Pattern Recognition, Automated
perturbation-enhanced MRSI
therapy response detection
Tumor Burden
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non‐invasive monitoring of response to treatment of glioblastoma (GB) is nowadays carried out using MRI. MRS and MR spectroscopic imaging (MRSI) constitute promising tools for this undertaking. A temozolomide (TMZ) protocol was optimized for GL261 GB. Sixty‐three mice were studied by MRI/MRS/MRSI. The spectroscopic information was used for the classification of control brain and untreated and responding GB, and validated against post‐mortem immunostainings in selected animals. A classification system was developed, based on the MRSI‐sampled metabolome of normal brain parenchyma, untreated and responding GB, with a 93% accuracy. Classification of an independent test set yielded a balanced error rate of 6% or less. Classifications correlated well both with tumor volume changes detected by MRI after two TMZ cycles and with the histopathological data: a significant decrease (p 
ISSN:0952-3480
1099-1492
DOI:10.1002/nbm.3194